Inovio Pharmaceuticals (NSDQ:INO) said today that the FDA placed a hold on its proposed Phase III clinical program for its investigational DNA immunotherapy candidate designed to treat pre-cancers and cancers caused by human papillomavirus.
The California-based company completed a randomized, double-blind Phase II trial of the candidate in July 2014, evaluating the DNA immunotherapy treatment in women with cervical intraepithelial neoplasia associated with HPV. The candidate met its efficacy endpoints, inducing regression of precancerous cervical disease and clearing HPV infection with robust T cell responses.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA delays Inovio phase III trial of DNA immunotherapy candidate appeared first on MassDevice.
from MassDevice http://ift.tt/2eEAnly
Cap comentari:
Publica un comentari a l'entrada